Welcome, Guest. Please login or register.
November 27, 2024, 06:33:00 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 250
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 160
Total: 160

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Merck MK-3682 & 8408 Study  (Read 6660 times)

0 Members and 2 Guests are viewing this topic.

Offline Onefluover

  • Member
  • Posts: 41
Merck MK-3682 & 8408 Study
« on: July 06, 2016, 09:56:15 pm »
Was just notified (after applying almost a year ago) that I have been accepted -or chosen- to participate in a trial study.  :) It is non-random. :) :) it will begin next month (August). I'm not finding anything archived here on these two drugs. Does anyone know anything about them that I should know about? Below is a bit of info and links:

Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02759315?term=MK-3682+and+MK-8408&rank=5   (please note there have been a few protocol amendments, so criteria may vary a little). Treatment duration will be 8 or 12 weeks.
 
This is a Phase 2 Merck study assessing the safety/effectiveness of MK-3682 and MK-8408 for 8, 12, and possibly 16 weeks of treatment. These drugs were previously studied in combination with a third drug, and now they are determining if the double combo is as effective as the triple. As far as drug class goes, the regimen would be similar to Epclusa (Sovaldi/Velpatasvir). MK-3682 is an NS5B polymerase inhibitor and MK-8408 is an NS5A replication complex inhibitor.
 
Prior studies with the triple drug combo had cure rates over 90% for genotype 3, so we are hoping to see similar cure rates with the double drug combination.
 
http://www.businesswire.com/news/home/20151116005459/en/Merck-Announces-Presentation-Results-Phase-2-Studies
51 M HAV/HBV Im., HCV-G3a
Fibrospect 2 <16 (F0/1) VL 4M
Expsd 1984-1992 (?) dx 1992
First tx attempt 2015
Liver 18.6 cm, relatively course & echogenic w/ diffuse hepatocellular process. 
Abnormal labs: ALT 163, AST 73, Chol 118, HDL Chol 30, IGA .05, Ferritin 648, Iron Bind Cap 296, Iron Sat 60%
Signs & symptoms: Freq. severe headache, very high BP, abdominal pain, distentia, joint pain, dbl vis., white nails, Schamberg's Dis., nausea, mild Jaundice, dark urine, non-hereditary Hemochromatosis.

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.